PMID- 23809433
OWN - NLM
STAT- MEDLINE
DCOM- 20131126
LR  - 20211021
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Print)
IS  - 1347-9032 (Linking)
VI  - 104
IP  - 10
DP  - 2013 Oct
TI  - CA-S27: a novel Lewis a associated carbohydrate epitope is diagnostic and 
      prognostic for cholangiocarcinoma.
PG  - 1278-84
LID - 10.1111/cas.12222 [doi]
AB  - Early and specific diagnosis is critical for treatment of cholangiocarcinoma 
      (CCA). In this study, a carbohydrate antigen-S27 (CA-S27) monoclonal antibody 
      (mAb) was established using pooled CCA tissue-extract as immunogen. The epitope 
      recognized by CA-S27-mAb was a new Lewis-a (Le(a)) associated modification of 
      MUC5AC mucin. A Soybean agglutinin/CA-S27-mAb sandwich ELISA to determine CA-S27 
      in serum was successfully developed. High level of CA-S27 was detected in serum 
      of CCA patients and could differentiate CCA patients from those of 
      gastro-intestinal cancers, hepatomas, benign hepatobiliary diseases and healthy 
      subjects with high sensitivity (87.5%) and high negative predictive value 
      (90.4%). The level of serum CA-S27 was dramatically reduced after tumor removal, 
      indicating tumor origin of CA-S27. Patients with high serum CA-S27 had 
      significantly shorter survivals than those with low serum CA-S27 regardless of 
      serum MUC5AC levels. Fucosyltransferase-III (FUT3) was shown to be a regulator of 
      CA-S27 expression. Suppression of CA-S27 expression with siRNA-FUT3 or 
      neutralization with CA-S27 mAb significantly reduced growth, adhesion, invasion 
      and migration potentials of CCA cells in vitro. In summary, we demonstrate that 
      serum CA-S27, a novel carbohydrate antigen, has potential as diagnostic and 
      prognostic markers for CCA patients. CA-S27 involves in promoting cell growth, 
      adhesion, migration and invasion of CCA cells.
CI  - (c) 2013 Japanese Cancer Association.
FAU - Silsirivanit, Atit
AU  - Silsirivanit A
AD  - Department of Biochemistry, Liver Fluke and Cholangiocarcinoma Research Center, 
      Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; Department of 
      Tumor Genetics and Biology, Graduate School of Medical Sciences, Kumamoto 
      University, Kumamoto, Japan.
FAU - Araki, Norie
AU  - Araki N
FAU - Wongkham, Chaisiri
AU  - Wongkham C
FAU - Vaeteewoottacharn, Kulthida
AU  - Vaeteewoottacharn K
FAU - Pairojkul, Chawalit
AU  - Pairojkul C
FAU - Kuwahara, Kazuhiko
AU  - Kuwahara K
FAU - Narimatsu, Yoshiki
AU  - Narimatsu Y
FAU - Sawaki, Hiromichi
AU  - Sawaki H
FAU - Narimatsu, Hisashi
AU  - Narimatsu H
FAU - Okada, Seiji
AU  - Okada S
FAU - Sakaguchi, Nobuo
AU  - Sakaguchi N
FAU - Wongkham, Sopit
AU  - Wongkham S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130806
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Neoplasm)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Epitopes)
RN  - 0 (Lewis Blood Group Antigens)
RN  - 0 (Lewis a oligosaccharide)
RN  - 0 (MUC5AC protein, human)
RN  - 0 (Mucin 5AC)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Oligosaccharides)
RN  - EC 2.4.1.- (Fucosyltransferases)
RN  - EC 2.4.1.65 (3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase)
SB  - IM
MH  - Aged
MH  - Amino Acid Sequence
MH  - Antibodies, Monoclonal/immunology
MH  - Antibodies, Neoplasm/immunology
MH  - Antigens, Neoplasm/blood/*immunology
MH  - Bile Duct Neoplasms/chemistry/*diagnosis/immunology
MH  - Bile Ducts, Intrahepatic/chemistry/*immunology
MH  - Cell Adhesion/physiology
MH  - Cholangiocarcinoma/chemistry/*diagnosis/immunology
MH  - Diagnosis, Differential
MH  - Digestive System Neoplasms/diagnosis
MH  - Epithelial Cells/chemistry/immunology
MH  - Epitopes/blood/*immunology
MH  - Female
MH  - Fucosyltransferases/antagonists & inhibitors/physiology
MH  - Humans
MH  - Lewis Blood Group Antigens
MH  - Liver Diseases/diagnosis
MH  - Male
MH  - Middle Aged
MH  - Molecular Sequence Data
MH  - Mucin 5AC/blood/chemistry/*immunology
MH  - Neoplasm Invasiveness
MH  - Neoplasm Proteins/antagonists & inhibitors/physiology
MH  - Oligosaccharides/*immunology
MH  - Predictive Value of Tests
MH  - RNA Interference
MH  - Sensitivity and Specificity
MH  - Survival Analysis
MH  - Tumor Cells, Cultured/metabolism/pathology
PMC - PMC7656540
EDAT- 2013/07/03 06:00
MHDA- 2013/12/16 06:00
PMCR- 2013/10/01
CRDT- 2013/07/02 06:00
PHST- 2013/04/03 00:00 [received]
PHST- 2013/06/17 00:00 [revised]
PHST- 2013/06/18 00:00 [accepted]
PHST- 2013/07/02 06:00 [entrez]
PHST- 2013/07/03 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
PHST- 2013/10/01 00:00 [pmc-release]
AID - CAS12222 [pii]
AID - 10.1111/cas.12222 [doi]
PST - ppublish
SO  - Cancer Sci. 2013 Oct;104(10):1278-84. doi: 10.1111/cas.12222. Epub 2013 Aug 6.